Background: Selection of first-line antiretroviral therapy requires consideration of efficacy as well as effects on lipids given the increased concern about cardiovascular risk in HIV-1 patients. Methods: ARTEN is a randomized, open-label, noninferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/ emtricitabine (FTC) 200 mg once daily, in antiretroviralnaive HIV-1 patients with CD4 + T-cell counts <400 (men) and <250 cells/mm 3 (women). The primary end point was plasma HIV RNA<50 copies/ml at two consecutive visits prior to week 48. Results: A total of 569 patients were randomized and treated. Overall, 66.8% of NVP and 65.3% of ATZ/r patients achieved the primary end point (difference 1.9%, 95% CI -5.9-9.8%). Similar rates of serious adverse events were observed (9.6% on NVP versus 8.8% on ATZ/r), although discontinuations due to adverse events were more frequent with NVP than ATZ/r (13.6% versus 3.6%, respectively). None of the 28 patients virologically failing ATZ/r selected resistance mutations, while they were selected in 29/44 patients virologically failing NVP. NVP induced a significantly greater increase in high-density lipoprotein cholesterol (HDL-c) and apolipoprotein A1 from baseline than ATZ/r, whereas triglycerides increased significantly more with ATZ/r than NVP. Mean change from baseline in TC:HDL-c ratio was -0.24 for NVP and 0.13 for ATZ/r (P=0.0001). Conclusions: NVP demonstrated at week 48 non-inferior antiviral efficacy compared with ATZ/r when given along with TDF/FTC, despite more drug-related discontinuations with NVP than ATZ/r. NVP was associated with a lower atherogenic lipid profile than ATZ/r although resistance mutations were more frequently selected with NVP than ATZ/r.
Introduction
transcriptase inhibitor (NNRTI), a ritonavir-boosted protease inhibitor (PI/r) or raltegravir [1] [2] [3] [4] . Among NRTIs, emtricitabine co-formulated with tenofovir disoproxil fumarate (TDF/FTC) is the most prescribed NRTI backbone [5] . Worldwide, nevirapine (NVP) is currently the most widely used third agent for HIV-1 treatment, with large experience providing sustained virological and immunological responses [6, 7] . Interestingly, NVP has been consistently associated with a favourable lipid profile [6] [7] [8] [9] [10] ; however, only limited trial data on NVP used in combination with TDF/FTC are available. Preferred PIs for first-line therapy include atazanavir co-administered with ritonavir (ATZ/r) [1] [2] [3] [4] . Data from the CASTLE study indicate that in antiretroviral (ARV)-naive patients, ATZ/r depicts similar antiviral efficacy to lopinavir/r [11] . Moreover, ATZ/r shows a more favourable lipid profile compared with many other PI/r [11] [12] [13] [14] [15] .
The aim of the ARTEN study was to compare the efficacy and safety of NVP versus ATZ/r, each in combination with TDF/FTC, in HIV-1 ARV-naive patients. NVP was administered as either 400 mg once daily or 200 mg twice daily in separate study arms. This is the first large prospective clinical trial to apply the CD4 + T-cell count thresholds recommended when initiating NVP therapy. The week 48 primary efficacy and the safety data are reported here.
Methods

Study population
Patients were recruited at 68 sites in Argentina, Germany, Italy, Mexico, Poland, Portugal, Romania, Spain, Switzerland and the UK from November 2006 to February 2007. Inclusion criteria required confirmed HIV-1 infection, age ≥18 years, creatinine clearance ≥50 ml/min and no prior ARV exposure for >7 days. Only males with CD4 + T-cell counts <400 cells/mm 3 and females with <250 cells/mm 3 were enrolled. Patients were excluded if they had liver cirrhosis stage Child-Pugh B or C, laboratory values ≥ Division of AIDS (DAIDS) grade 3 (grade 4 for triglycerides) or chronic hepatitis B/C with transaminases above 2.5-fold of the upper limit of normal. The study was done in accordance with the ethical principles in the Declaration of Helsinki. Written informed consent was obtained from all subjects. The trial was approved by the local Ethics Committees.
Study design
In this open-label, multicentre, non-inferiority study, patients were randomized (1:1:1) to receive: NVP 200 mg twice daily, NVP 400 mg once daily or ATZ/r 300 mg/100 mg once daily, each given with fixeddose TDF 300 mg/FTC 200 mg once daily. Patients randomized to either NVP dose started out with a 14-day lead-in dose of NVP 200 mg once daily. Randomization was stratified according to plasma HIV RNA (> or ≤100,000 copies/ml) and CD4 + T-cell counts (≥ or <50 cells/mm 3 ) at screening. All patients underwent genotypic resistance testing. Patients with TDF, FTC, NVP or ATZ resistance-associated mutations were excluded.
Patients were assessed at screening, baseline and at weeks 2, 4, 6, 8, 12, 24, 36 and 48, or at early termination. Plasma HIV RNA, CD4 + T-cell counts and safety laboratory analyses (haematology, blood chemistry and urinalysis) were performed at all patient visits except weeks 2 and 6 when only liver function tests were performed. All laboratory analyses, including plasma HIV RNA (Cobas Amplicor HIV-1 Monitor version 1.5; Roche, Basel, Switzerland) and CD4 + T-cell count measurements, were performed at a central laboratory (MDS Pharma Services, Hamburg, Germany). Investigators judged the severity of adverse events (AEs) during the study using the DAIDS Standardized Toxicity Table for Grading Severity of Adverse Experiences [16] , and assessed the relationship to the study medication.
The primary end point at week 48 was treatment response, defined as plasma HIV RNA<50 copies/ml measured at two consecutive visits prior to week 48 (for example, at weeks 24 and 36) and without subsequent rebound or change of ARV therapy prior to week 48. This restrictive end point was chosen based on current 2005 EACS guidelines at the time the trial was designed [17] . The most recent IAS guidelines, however, are also much in-line with this criterion, specifically stating that 'effective therapy should result in suppression to <50 copies/ml by 24 weeks' [1] . Viral rebound was defined as two consecutive values ≥50 copies/ml at least two weeks apart. A key secondary end point for sensitivity analyses was confirmed plasma HIV RNA<50 copies/ml at week 48 using the time-to-loss of virological response (TLOVR) algorithm, which defines treatment response as plasma HIV RNA<50 copies/ml at two consecutive visits up to week 48 (for example, at weeks 36 and 48). Change in CD4 + T-cell count from baseline through to week 48, the proportion of patients with virological failure, the specific drug resistance mutations among those experiencing virological failure and lipid changes were also evaluated. Safety end points included the incidence of AEs, serious AEs, discontinuations due to AEs and DAIDS grade ≥3 laboratory abnormalities, as well as mean changes from baseline in laboratory values over time. The safety assessment period was up to database lock (beyond week 48).
Statistical analyses
Assuming a response rate of 65% for the primary end point in the NVP (twice daily and once daily combined) and ATZ/r groups, a sample size of 561 patients was calculated (374 on NVP and 187 on ATZ/r) in order to provide 80% power to demonstrate that the combined NVP-based regimens were non-inferior to the ATZ/r-based regimen using a non-inferiority margin of -12%.
The calculation of the difference in the proportion of responders and the CI were adjusted for the stratification used in the randomization, that is, screening categories of plasma HIV RNA (> or ≤ 100,000 copies/ml) and CD4 + T-cell counts (≥ or <50 cells/mm 3 ). Secondary efficacy analyses of the primary end point, comparing each individual NVP group with ATZ/r, were only performed if non-inferiority for the combined NVP group versus ATZ/r was demonstrated in the primary analysis.
Statistical analysis of efficacy was performed on all randomized, evaluable patients who took at least one dose of the study medication. Patients who dropped out of the study due to AEs, lack of treatment efficacy, lost to follow-up or discontinuation for any other reason were included in the efficacy analysis. An intention-to-treat (ITT) analysis was performed, with all withdrawals or dropouts prior to week 48 (non-completers) considered as failures. Additionally, analyses of the set of patients on treatment (OT) at week 48 were performed.
Genotypic resistance testing was performed on specimens from all patients who met the criteria for virological failure. It was assessed by searching for all NRTI, NNRTI and PI resistance-associated mutations using the Virco ® Type HIV-1 assay (Virco, Mechelen, Belgium). Mean changes in fasting lipids from baseline were assessed with the last observation carried forward (LOCF). All statistical analyses were two-sided and performed using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA). This study is registered with ClinicalTrials. gov number NCT00389207.
Results
Of the 710 patients originally assessed for trial eligibility, only 5% were excluded due to high CD4 + T-cell counts. A total of 569 HIV-1, ARV-naive individuals were randomized, treated and included in the efficacy analysis. Of these, 70.8% were from Western Europe, 21.4% from Latin America and 7.7% from Eastern Europe. Ethnic groups represented were Caucasian (80.0%), Asian (12.1%) and Black (7.9%). By week 48, 43/188 (22.9%) patients treated with NVP once daily and 56/188 (29.8%) treated with NVP twice daily had either discontinued the study medication or had missing follow-up information ( Figure 1 ). Among all NVP patients, 47/376 (12.5%) discontinued due to AEs by week 48: 20/188 (10.6%) in the NVP once daily group and 27/188 (14.4%) in the NVP twice daily group. In comparison, 18/193 (9.3%) patients in the ATZ/r group had discontinued treatment by week 48, with 5/193 (2.6%) of these due to AEs.
Baseline demographics were similar between treatment groups (Table 1) . Overall, 62.8% of patients in the combined NVP group and 65.8% in the ATZ/r group had baseline plasma HIV RNA>100,000 copies/ ml. Mean baseline CD4 + T-cell counts were 182 and 188 cells/mm 3 in the combined NVP and ATZ/r groups, respectively. HIV-1 non-B subtypes were present in 132 (23.2%) patients, with A, C, F, CRF02_AG and CRF12_BF being the most common.
At week 48, similar proportions of patients (combined NVP versus ATZ/r) achieved the primary end point of treatment response in the ITT analysis ( Table 2 ). Non-inferiority of combined NVP arms compared with ATZ/r was established in the primary analysis, with the non-inferiority margin of -12% being excluded from the 95% CI. This result was supported by all the pre-planned sensitivity analyses, including confirmed virological response at week 48 following the TLOVR algorithm. However, a post-hoc analysis performed using the 'snapshot' analysis (single measurement), whereby patients with no virological data in the week 48 time window were considered as failures showed a lower response rate for NVP compared with ATZ/r (67.3% versus 78.8%; P=0.003), mainly as consequence of the larger proportion of NVP patients without virological data in the week 48 window. These results, however, are counterbalanced in the analysis of patients with data in the week 48 window (OT), which show a higher response rate with NVP than with ATZ/r ( Table 2) . When the primary end point was used, noninferiority was also established between each of the individual NVP groups and the ATZ/r group at week 48; 125/188 (66.5%) NVP twice daily patients (difference [95% CI] versus ATZ/r 1.5% [-7.7-10.7] ), 126/188 (67.0%) NVP once daily patients (difference [95% CI] versus ATZ/r 2.5% [-6.5-11.5]) and 126/193 (65.3%) ATZ/r patients achieved the primary end point.
Treatment response (primary end point) at week 48 was also assessed by plasma HIV RNA at screening. In patients with >100,000 copies/ml, treatment response rates were generally lower than in patients with ≤100,000 copies/ml. In patients with baseline plasma HIV RNA>100,000 copies/ml, the combined NVP group had numerically higher treatment response rates than ATZ/r (138 according to investigator judgement. In two of these patients, drug resistance mutations were unexpectedly present at baseline (study protocol violation). Another patient was rated as a virological failure by the investigator despite having plasma HIV RNA<50 copies/ ml at week 36 and records stated that the patient did not return to the site and so he was lost-to follow-up. Another patient had plasma HIV RNA>200,000 copies/ml at baseline, which decreased to 120 copies/ml at week 12, but the investigator discontinued therapy judging that treatment had failed. In another two NVP twice daily patients, non-compliance appeared to be associated with virological failure. In the NVP once daily group, 11/188 patients (5.9%) discontinued treatment due to lack of efficacy, as determined by the investigator. In two of them, compliance was poor as mentioned in the clinical chart. Among patients with virological failure in the NVP treatment arms, the most frequent NNRTI resistance mutation was Y181C/I/V/S, occurring in 9/20 NVP once daily and 15/24 NVP twice daily patients. Other NNRTI resistance changes were less frequent, such as K103N/S/T, V106A/M, V108I/M/V and K101E/R, and appeared in another five individuals failing on NVP. The most frequent NRTI resistance mutations in the NVP treatment arms were M184V/I in 25 (10 once daily and 15 twice daily) and K65R in 12 (4 once daily and 8 twice daily) patients. In the ATZ/r arm, 3/193 patients (1.6%) discontinued treatment due to lack of efficacy. No FTC, TDF or ATZ resistance mutations were detected among the 28 ATZ/r patients with virological failure. Compared with NVP-treated subjects, a larger proportion of ATZ/r patients were OT but without confirmed virological response at week 48 (9 [4.8%], 3 [1.6%] and 25 [13. 0%] patients in the NVP once daily, NVP twice daily and ATZ/r groups, respectively).
Mean changes in fasting high density lipoprotein cholesterol (HDL-c) and apolipoprotein A1 from baseline to week 48 were significantly higher with NVP than with ATZ/r treatment (Figure 2) . Although a significantly greater increase in low-density lipoprotein cholesterol (LDL) cholesterol (LDL-c) and total cholesterol was observed in the combined NVP group compared with ATZ/r, the mean total cholesterol (TC):HDL-c ratio was reduced with NVP but increased with ATZ/r (P=0.0001). Moreover, no significant differences were recognized comparing apolipoprotein B changes in NVP and ATZ/r groups, whereas apolipoprotein A increased significantly more in patients on NVP than ATZ/r (P<0.0001). In addition, triglyceride levels remained almost unchanged in patients treated with NVP, but increased with ATZ/r.
The safety population analysis included all 569 treated patients (376 NVP and 193 ATZ/r). The assessment period was up to the database lock (beyond week 48). Mean treatment time up to database lock for the safety analysis was 371.5 days, 343.4 days and 418.4 days for the NVP once daily, NVP twice daily and ATZ/r groups, respectively. Overall, the proportion of patients with AEs was similar between groups (85.9% of NVP versus 86.5% of ATZ/r patients). Despite similar AE rates and a lower incidence of drug-related AEs in the combined NVP group (34.6% versus 48.7%), discontinuations due to AEs were higher with NVP than with ATZ/r (13.6% versus 3.6%), with the difference mainly due to rash (5.1% versus 0%). Five deaths were reported, two in each NVP group and one in the ATZ/r group; none were considered to be related with the study medication.
Serious AEs were reported in 36/376 (9.6%) patients in the combined NVP group and in 17/193 (8.8%) patients in the ATZ/r group. Infections were the most common serious AE, seen in 2.9% of NVP patients and 5.2% of ATZ/r patients. Few serious AEs were considered to be related to the study medication.
Rash was the most frequent cause of treatment discontinuation among NVP recipients. Although the overall incidence of rashes was comparable between NVP and ATZ/r (16.0% versus 12.4%, respectively), rashes with NVP tended to be more severe and occurred earlier following treatment initiation. The majority of discontinuations in the NVP group were due to mild to moderate rash (DAIDS grade 1 and 2), with 14 epidermal necrolysis or deaths due to skin or liver toxicity occurred. Treatment-related DAIDS grade ≥3 AEs are summarized in Table 3 . The incidence of DAIDS grades 3/4 alanine aminotranferase (ALT)/aspartate aminotransferase (AST) increases was 8.5% (32/376) in the combined NVP group and 2.6% (5/193) in the ATZ/r group (P=0.01). As expected with NVP, they occurred most frequently during the first 16 weeks of therapy, decreasing in frequency thereafter. DAIDS grades 3 and 4 bilirubin increases were observed in 44.6% and 8.8% of patients on ATZ/r, and 1.6% and 1.6% in NVP patients, respectively. However, only one patient in the ATZ/r group discontinued treatment due to hyperbilirubinaemia.
Finally, because all patients enrolled in ARTEN received TDF, the evolution of renal function tests was evaluated. The mean glomerular filtration rate decreased from baseline to last control in all treatment arms, but it was significantly more pronounced with ATZ/r than with NVP (7.4 ±15.1 versus 3.3 ±16.2; P=0.02). However, only 3 out of 569 patients developed renal insufficiency, two in the ATZ/r arm and one in the NVP arm. Only the NVP patient discontinued therapy for this reason. No DAIDS grade 4 creatinine increases were seen in the study.
Discussion
The results of the ARTEN trial show that, when used in combination with TDF/FTC, the virological efficacy of NVP is non-inferior to ATZ/r in ARV-naive HIV-1 patients over 48 weeks, using the originally planned treatment response criteria. The results were confirmed using the TLOVR algorithm. By contrast, the snapshot analysis, whereby patients with no virological data in the week 48 time window are considered as failures, was more favourable to ATZ/r as more patients on NVP than ATZ/r had discontinued earlier due to side effects. Furthermore, the response rate was higher for patients OT with NVP than ATZ/r at week 48. This is the first large trial that used the CD4 + T-cell thresholds recommended for initiating NVP therapy (<250 cells/ mm 3 in women and <400 cells/mm 3 in men) in a prospective manner. The proportion of patients with baseline plasma HIV RNA>100,000 copies/ml was ≥62% in all treatments arms and higher than in previous trials (<35% in the 2NN Study on NVP) and ATZ/r (51% in the CASTLE Study on ATZ/r) [6, 12] . This is consistent with the fact that a substantial proportion of newly diagnosed HIV-1 individuals currently presents with advanced HIV disease [18, 19] . The majority of these late-presenting patients would be expected to be within the CD4 + T-cell count thresholds desirable for initiating NVP therapy. However, because most recent ARV treatment guidelines [1, 2, 4] encourage treatment of HIV-1 individuals at earlier disease stages, a note of caution regarding the use of NVP in subjects with increased CD4 + T-cell counts is warranted. The primary end point of treatment response in ARTEN was chosen to reflect the recommendations of the EACS 2005 guidelines, which stated that a major treatment objective in ARV-naive patients was to achieve plasma HIV RNA<50 copies/ml at 24 weeks of therapy [17] . Therefore, the primary end point was defined as the proportion of patients with HIV RNA<50 copies/ml at two consecutive visits prior to week 48, for example, weeks 24 and 36. This criterion is more stringent than the US FDA-required end point of a confirmed virological response <50 copies/ml up to week 48 according to the TLOVR algorithm [20] , which also was selected as a sensitivity analysis to support the results of the primary end point. NVP demonstrated non-inferior efficacy to ATZ/r for the primary end point and all pre-specified sensitivity analyses. In addition, non-inferiority was also established between each of the individual NVP dosing groups and the ATZ/r arm for the primary end point. Among patients with low and high baseline plasma HIV RNA, numerical differences in the proportion of responders were observed between the study groups. In patients with baseline HIV RNA≥100,000 copies/ ml, NVP appeared slightly more effective than ATZ/r, whereas conversely in patients with baseline HIV RNA<100,000 copies/ml, ATZ/r was slightly more effective, although differences did not reach statistical significance. A lower antiviral efficacy of ARV regimens in the subset of patients with higher baseline viraemia has been noticed in other trials [11, 21] .
Recently, two small clinical studies reported a high rate of virological failure in ARV-naive patients receiving NVP in combination with TDF and either lamivudine or FTC [22, 23] . However, in our large, adequately powered, randomized, multinational ARTEN study, we show that NVP in combination with TDF/FTC provides good efficacy in an advanced ARV-naive population, with no difference in the rate of virological failure over 48 weeks when compared with ATZ/r. Although virological failure rates were similar across the treatment groups, more patients in the NVP arms were prematurely discontinued due to investigator-considered virological failure. Two other large studies have recently confirmed the good performance of regimens combining NVP with TDF/FTC [24, 25] . In the OCTANE Trial 2 (ACTG A5208), NVP and lopinavir/r, all along with TDF/FTC displayed equivalent virological efficacy in 500 African women with low CD4 + T-cell counts and who had never been exposed to single-dose NVP as prophylaxis for vertical HIV infection. However, as in ARTEN, discontinuations due to AEs were more frequent in NVP than in the PI arms [25] .
Marked reductions in morbidity and mortality rates, leading to longer survival in the HAART era, have raised the importance of minimizing ARV-related side effects [26] . Potency, tolerability and metabolic side effects of treatment should now be considered when choosing an initial regimen. Dyslipidaemia and insulin resistance, both well-known cardiovascular risk factors, are common ARV-related metabolic effects that are of increasing concern [27] , and some drugs may play a more important role than others [28] [29] [30] . Although the metabolic disturbances induced by ARVs can be treated pharmacologically [31] , an alternative strategy would be to select ARVs with a low-risk metabolic profile [32] . Although both NVP and ATZ have been associated with a favourable lipid profile [6, [8] [9] [10] [11] [12] 33] , the ARTEN results point out that NVP provides a potentially less atherogenic lipid profile than ATZ/r. Increased levels of HDL-c and apolipoprotein A1 have been associated with a decreased risk of coronary heart disease [34, 35] . In ARTEN, NVP was associated with marked and significantly greater increases in HDL-c and apolipoprotein A1 compared with ATZ/r. Despite a greater increase in LDL-c and TC with NVP, a significant difference was observed in the effect on the TC:HDL-c ratio, which improved with NVP treatment but worsened with ATZ/r. Whether the observed differences in the lipid profile between NVP and ATZ/r confer clinical benefits by reducing cardiovascular risk is unknown but it is in-line with the lower rate of cardiovascular events observed with NNRTIs versus PIs in the D:A:D study [29] .
No unexpected safety concerns were raised during the trial and the proportion of patients with AEs and serious AEs was comparable between treatment groups. However, substantially more patients in the NVP groups discontinued treatment due to AEs compared with ATZ/r. This may have been biased by the open-label nature of the study and the well-known side effect profile of NVP. For instance, early discontinuations due to mild rash in NVP treated patients were relatively common, whereas only one individual discontinued ATZ/r due to hyperbilirubinaemia, despite DAIDS grades 3/4 bilirubin values being reported in 53% of ATZ/r patients. Differences in study populations may explain why the incidence of severe hyperbilirubinaemia in other ATZ/r trials has been lower, in the range of 34% [11, 36] . Currently, most physicians consider hyperbilirubinaemia associated with ATZ therapy mainly as a cosmetic problem. Finally, because ARTEN enrolled a relatively large number of patients that were exposed to TDF, the assessment of renal toxicity events was of interest; over 48 weeks the mean glomerular filtration rate decreased in all patients, being more pronounced in the ATZ/r than in the NVP arm. Three patients developed renal insufficiency: two on ATZ/r and one on NVP.
In prior NVP studies conducted in patients with CD4 + T-cell counts above the given thresholds, the incidence of DAIDS grade 3/4 ALT/AST increases has been reported to be up to 14% [6] . In ARTEN, DAIDS grade 3/4 ALT/AST increases were seen in only 8.5% of patients on NVP, with no differences between once daily and twice daily dosing. This supports the recommendation to adhere to the CD4 + T-cell thresholds when initiating NVP in treatment-naive patients in order to reduce the incidence of liver enzyme increases. As in other studies, which have evaluated PIs and/or NNRTIs [6, 7, 11, 21, 25, 36] , selection of drug resistance in ARTEN in patients failing virologically was more frequent in the NVP than ATZ/r arms, a finding that may have implications for the selection of rescue ARV regimens. The frequent recognition of mutations at codon 181 in NVP failures might further compromise the activity of etravirine [37] .
With the increasing interest in compartmentalization and effects of different ARV drugs [38] , it seems worthwhile to highlight that NVP has excellent penetration into compartments such as the central nervous system and the genital tract, which contrasts with ATZ/r [39] [40] [41] . A further consideration is the cost. The use of less expensive ARV medications is increasingly being prioritized in many developed countries, such as the UK, where this is becoming a real concern for clinicians in charge of their own drug budget. In this regard, NVP is on average a quarter the price of ATZ/r [42] . Although consideration of drug cost has generally been disregarded in most treatment guidelines so far, it is clear that budget constraints will increasingly influence prescriptions choices. In line with this fact, the most recent European [2] and WHO [43] ARV treatment guidelines offer a wider range of drugs (among which is NVP) for first-line therapy than the US DHHS guidelines [4] .
In summary, in the ARTEN Trial NVP demonstrated non-inferior antiviral efficacy to ATZ/r at week 48 in ARV-naive HIV-1 patients using the planned treatment response criteria. Thus, NVP used in conjunction with TDF/FTC may be considered a good alternative option as first-line ARV therapy, especially in patients with high cardiovascular risk. Similar results were observed in both the NVP once daily and twice daily dosing groups, confirming results from a multicohort study [44] . The results of ARTEN also support the application of the recommended CD4 + T-cell thresholds when initiating first-line NVP therapy in order to reduce the rate of liver enzymes increases.
